Kirin Holdings Co Ltd
XMUN:KIR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Kirin Holdings Co Ltd
XMUN:KIR
|
JP |
|
W
|
Woodside Energy Group Ltd
F:WOP0
|
AU |
|
TechnipFMC PLC
NYSE:FTI
|
UK |
|
Vend Marketplaces ASA
F:XPGB
|
NO |
|
LVMH Moet Hennessy Louis Vuitton SE
OTC:LVMHF
|
FR |
|
W
|
Walt Disney Co
SWB:WDP
|
US |
|
Patterson-UTI Energy Inc
NASDAQ:PTEN
|
US |
|
Kuaishou Technology
LSE:0A74
|
CN |
|
Naspers Ltd
F:NNW
|
ZA |
|
Italgas SpA
MIL:IG
|
IT |
|
U
|
US Bancorp
F:UB5
|
US |
|
DXC Technology Co
NYSE:DXC
|
US |
|
Vonovia SE
XETRA:VNA
|
DE |
|
NextNav Inc
F:KK0
|
US |
|
B
|
Banco Santander SA
WSE:SAN
|
ES |
|
D
|
Dr Reddy's Laboratories Ltd
BSE:500124
|
IN |
|
JPMorgan Chase & Co
F:CMC
|
US |
|
C
|
Compass Minerals International Inc
SWB:CM8
|
US |
Kirin Holdings Co Ltd
Kirin Holdings is a Japanese company best known for making and selling drinks. Its business includes beer, chu-hi, other alcoholic beverages, soft drinks, and drinks with functional or health-focused ingredients. It also owns health science and pharmaceutical businesses, so it is not just a beverage company but a group that sells both consumer drinks and medical products. The company makes money in two main ways. First, it sells branded drinks through supermarkets, convenience stores, restaurants, and other retail channels. Second, through its health science and drug businesses, it sells medicines and related products to hospitals, doctors, pharmacies, and patients. That gives Kirin a mix of consumer-facing sales and healthcare sales. What makes Kirin different is that it sits between two very different industries: everyday beverages and medicine. In drinks, it competes on brand, taste, and shelf presence. In healthcare, it depends more on research, regulation, and product approval. That mix can make the business more resilient than a pure brewery because it is not tied to one market or one type of customer.
Kirin Holdings is a Japanese company best known for making and selling drinks. Its business includes beer, chu-hi, other alcoholic beverages, soft drinks, and drinks with functional or health-focused ingredients. It also owns health science and pharmaceutical businesses, so it is not just a beverage company but a group that sells both consumer drinks and medical products.
The company makes money in two main ways. First, it sells branded drinks through supermarkets, convenience stores, restaurants, and other retail channels. Second, through its health science and drug businesses, it sells medicines and related products to hospitals, doctors, pharmacies, and patients. That gives Kirin a mix of consumer-facing sales and healthcare sales.
What makes Kirin different is that it sits between two very different industries: everyday beverages and medicine. In drinks, it competes on brand, taste, and shelf presence. In healthcare, it depends more on research, regulation, and product approval. That mix can make the business more resilient than a pure brewery because it is not tied to one market or one type of customer.
Revenue: Reported revenue decreased by 1% year-on-year, mainly due to the sale of Lion Dairy & Drinks; underlying revenue actually increased by 4%.
Profit Pressures: COVID-19 had a significant negative impact on normalized operating profit, but reforms allowed a 3% year-on-year increase.
Impairment Losses: Impairment related to Myanmar Brewery and political risk led to a 29% decrease in profit attributable to owners.
Guidance Cut: Full-year guidance for normalized operating profit and profit attributable to owners was lowered, mainly due to challenges in Myanmar.
Health & Innovation: Strong growth in health-related beverages like LC-Plasma, with significant sales and raised revenue guidance for this segment.
Channel Performance: Off-premise sales outperformed during pandemic; on-premise sales remained challenged by restrictions.